Want to see HUMA full AI Analyst Report?
HUMA Stock Chart & Stats
$0.71
-$0.19(-4.01%)
At close: 4:00 PM EST
$0.71
-$0.19(-4.01%)
Day’s Range― - ―
52-Week Range$0.55 - $2.84
Previous CloseN/A
Volume1.64M
Average Volume (3M)14.49M
Market Cap
$179.23M
Enterprise Value$137.25
Total Cash (Recent Filing)$48.54M
Total Debt (Recent Filing)$65.90M
Price to Earnings (P/E)―
Beta2.88
Next Earnings
Aug 17, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding269,638,150
10 Day Avg. Volume7,519,048
30 Day Avg. Volume14,492,536
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)48.86
Price to Sales (P/S)74.54
P/FCF Ratio-1.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.96Price Target Upside175.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$6.51M
Bulls Say, Bears Say
Bulls Say
Phase 3 V012 Positive Interim ResultsA protocol-specified positive interim readout that stopped enrollment materially de-risks the dialysis indication and creates a clear regulatory pathway toward a supplemental BLA. Durable impact: faster access to a large hemodialysis market, stronger clinical credibility with surgeons and payers, and a concrete near-term commercialization catalyst that can underpin adoption and reimbursement discussions.
Regained Global Rights For SymvessRegaining ex-U.S. control gives Humacyte strategic flexibility to coordinate global regulatory filings, pricing and partnerships. Durable benefit: unified commercialization strategy, potential to capture higher long-term share and licensing value, and the ability to tailor market entry by region to maximize uptake and margins over multiple indications.
Underwritten Equity Offering Strengthens LiquidityA committed equity raise materially extends runway and reduces near-term financing risk, enabling planned regulatory filings, manufacturing scale-up and commercial launch activities. Over a 2–6 month horizon this improves financial flexibility, lowers likelihood of disruptive emergency financings, and supports execution of go-to-market plans.
Bears Say
Large Cash Burn & Deep LossesSustained, sizable negative cash flow reflects ongoing investment in R&D and commercialization without offsetting commercial revenue, driving persistent funding needs. Over months this forces reliance on external capital, increases dilution risk, and constrains the company’s ability to invest in manufacturing capacity, sales scale-up, or extended clinical programs if cash inflows slow.
High Leverage Relative To EquityMaterial debt levels against a thin equity base reduce financial resilience and raise refinancing risk, especially if commercial ramp or regulatory timelines slip. This structural leverage can force prioritization of near-term liquidity over strategic investments, elevate borrowing costs, and limit flexibility to respond to adverse outcomes in trials or market access negotiations.
Limited Commercial Scale & Adoption RiskDespite encouraging percentage growth, absolute Symvess revenue remains small and adoption is inconsistent across sites. Structurally this limits near-term margin expansion and cash generation, increases dependence on successful label expansion and payor coverage, and means commercialization investment may need to continue longer before achieving sustainable unit economics.
Humacyte News
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $0.55 and its highest was $2.84 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $179.23M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Aug 17, 2026 which is in 29 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on May 13, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.116 by $0.026.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.1.
How many shares outstanding does Humacyte have?
Humacyte has 269,638,150 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.116. Following the earnings report the stock price went up 24.176%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Humacyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.96 (175.82% Upside)
$1.96 (175.82% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 5.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $59.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.56%
12-Months-Change
Fundamentals
Return on Equity
-2781.56%
Trailing 12-Months
Asset Growth
-31.99%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
HUMA Stock 12 Month Forecast
Average Price Target
$1.96
▲(175.82% Upside)
Technical Analysis
Cartesian Therapeutics
―
Allogene Therapeutics
―
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
8.14% Insiders
4.80% Mutual Funds
0.03% Other Institutional Investors
82.05% Public Companies and
Individual Investors